Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells

Long,Cong; Guo,Wei; Zhou,Heng; Wang,Jingchao; Wang,Huan; Sun,Xiaoping

doi:10.3892/ijo.2016.3353

Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells

Authors:
- Cong Long
- Wei Guo
- Heng Zhou
- Jingchao Wang
- Huan Wang
- Xiaoping Sun
View Affiliations

Affiliations: Department of Pathogen Biology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Pathology and Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: January 25, 2016 https://doi.org/10.3892/ijo.2016.3353
Pages: 1519-1530

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) can establish a life-long persistence in the host after primary infection and is associated with certain malignancies, which are resistant to conventional chemotherapeutic agents with a poor prognosis. Latency-associated nuclear antigen 1 (LANA1) encoded by KSHV is essential for segregation, replication and maintenance of viral genome. In addition, LANA1 upregulates the transcriptional activity of signal transducer and activator of transcription 3 (STAT3), which plays an important role in promoting survival of KSHV-associated primary effusion lymphoma (PEL) cells. Furthermore, LANA1 mediates transcriptional modulation of KSHV and host genome in host cells. In the present study, the antitumor effect of triptolide was assessed. CCK-8 assays were performed to demonstrate that the proliferations of PEL cells were efficiently inhibited by triptolide in a dose- and time-dependent manner. Flow cytometric results indicated that triptolide induced cell cycle arrest and apoptosis. Western blot results suggested that triptolide downregulated LANA1 expression and reduced half-life of LANA1 in the KSHV-infected malignant cells. Viral titer experiments indicated that triptolide treatment impaired the number of viral DNA copies and the production of virions in BCBL-1 cells. Triptolide also suppressed STAT3 activity and inhibited secretion of IL-6 in PEL cells. In a mouse xenograft model of primary effusion lymphoma by BCBL-1 cells, triptolide treatment significantly inhibited ascites formation and diffused organ infiltration. These results indicate that triptolide impairs the expression of LANA1 and shows antitumor activity against PEL in vitro and in vivo. Triptolide may be a potential agent for treatment of PEL.

View Figures

View References

1	Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM and Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1865–1869. 1994. View Article : Google Scholar : PubMed/NCBI
2	Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S and Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 23:4372–4380. 2005. View Article : Google Scholar : PubMed/NCBI
3	Boshoff C and Chang Y: Kaposi's sarcoma-associated herpes-virus: A new DNA tumor virus. Annu Rev Med. 52:453–470. 2001. View Article : Google Scholar
4	Bottero V, Sadagopan S, Johnson KE, Dutta S, Veettil MV and Chandran B: Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation. J Virol. 87:11806–11820. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA and Lossos IS: Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA. 107:13069–13074. 2010. View Article : Google Scholar : PubMed/NCBI
6	Coen N, Duraffour S, Snoeck R and Andrei G: KSHV targeted therapy: An update on inhibitors of viral lytic replication. Viruses. 6:4731–4759. 2014. View Article : Google Scholar : PubMed/NCBI
7	Dyson OF, Walker LR, Whitehouse A, Cook PP and Akula SM: Resveratrol inhibits KSHV reactivation by lowering the levels of cellular EGR-1. PLoS One. 7:e333642012. View Article : Google Scholar : PubMed/NCBI
8	Lee GM, Shahian T, Baharuddin A, Gable JE and Craik CS: Enzyme inhibition by allosteric capture of an inactive conformation. J Mol Biol. 411:999–1016. 2011. View Article : Google Scholar : PubMed/NCBI
9	Verma SC, Lan K and Robertson E: Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol. 312:101–136. 2007.
10	Sun Q, Tsurimoto T, Juillard F, Li L, Li S, De León Vázquez E, Chen S and Kaye K: Kaposi's sarcoma-associated herpesvirus LANA recruits the DNA polymerase clamp loader to mediate efficient replication and virus persistence. Proc Natl Acad Sci USA. 111:11816–11821. 2014. View Article : Google Scholar : PubMed/NCBI
11	Uppal T, Banerjee S, Sun Z, Verma SC and Robertson ES: KSHV LANA - the master regulator of KSHV latency. Viruses. 6:4961–4998. 2014. View Article : Google Scholar : PubMed/NCBI
12	Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, Hayward GS and Hayward SD: A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med. 9:300–306. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lu J, Jha HC, Verma SC, Sun Z, Banerjee S, Dzeng R and Robertson ES: Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin. J Virol. 88:4204–4217. 2014. View Article : Google Scholar : PubMed/NCBI
14	Paudel N, Sadagopan S, Chakraborty S, Sarek G, Ojala PM and Chandran B: Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions. J Virol. 86:5974–5991. 2012. View Article : Google Scholar : PubMed/NCBI
15	Verma SC, Borah S and Robertson ES: Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J Virol. 78:10348–10359. 2004. View Article : Google Scholar : PubMed/NCBI
16	Sun R, Liang D, Gao Y and Lan K: Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency. J Virol. 88:7331–7344. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sun Z, Xiao B, Jha HC, Lu J, Banerjee S and Robertson ES: Kaposi's sarcoma-associated herpesvirus-encoded LANA can induce chromosomal instability through targeted degradation of the mitotic checkpoint kinase Bub1. J Virol. 88:7367–7378. 2014. View Article : Google Scholar : PubMed/NCBI
18	Friborg J Jr, Kong W, Hottiger MO and Nabel GJ: p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 402:889–894. 1999.
19	Radkov SA, Kellam P and Boshoff C: The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retino-blastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 6:1121–1127. 2000. View Article : Google Scholar : PubMed/NCBI
20	Muromoto R, Okabe K, Fujimuro M, Sugiyama K, Yokosawa H, Seya T and Matsuda T: Physical and functional interactions between STAT3 and Kaposi's sarcoma-associated herpesvirus-encoded LANA. FEBS Lett. 580:93–98. 2006. View Article : Google Scholar
21	Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ and Bryan RF: Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc. 94:7194–7195. 1972. View Article : Google Scholar : PubMed/NCBI
22	Liu Q: Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 11:377–383. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhou ZL, Yang YX, Ding J, Li YC and Miao ZH: Triptolide: Structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep. 29:457–475. 2012. View Article : Google Scholar : PubMed/NCBI
24	Banerjee S, Sangwan V, McGinn O, Chugh R, Dudeja V, Vickers SM and Saluja AK: Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. J Biol Chem. 288:33927–33938. 2013. View Article : Google Scholar : PubMed/NCBI
25	Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM and Saluja AK: Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67:9407–9416. 2007. View Article : Google Scholar : PubMed/NCBI
26	Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, et al: A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 4:156ra1392012. View Article : Google Scholar : PubMed/NCBI
27	Sun X, Barlow EA, Ma S, Hagemeier SR, Duellman SJ, Burgess RR, Tellam J, Khanna R and Kenney SC: Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci USA. 107:3146–3151. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sun X, Bristol JA, Iwahori S, Hagemeier SR, Meng Q, Barlow EA, Fingeroth JD, Tarakanova VL, Kalejta RF and Kenney SC: Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J Virol. 87:10126–10138. 2013. View Article : Google Scholar : PubMed/NCBI
29	Zhou H, Guo W, Long C, Wang H, Wang J and Sun X: Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1. Biochem Biophys Res Commun. 456:815–820. 2015. View Article : Google Scholar
30	Chen W, Sin SH, Wen KW, Damania B and Dittmer DP: Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog. 8:e10030482012. View Article : Google Scholar : PubMed/NCBI
31	Lin X, Liang D, He Z, Deng Q, Robertson ES and Lan K: miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One. 6:e162242011. View Article : Google Scholar : PubMed/NCBI
32	Choi ES, Nam JS, Jung JY, Cho NP and Cho SD: Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer. Sci Rep. 4:71622014. View Article : Google Scholar : PubMed/NCBI
33	Pica F, Serafino A, Garaci E and Volpi A: Cidofovir on HHV-8 in BCBL-1 cells. Antivir Ther. 9:823–825. 2004.PubMed/NCBI
34	Aoki Y, Feldman GM and Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 101:1535–1542. 2003. View Article : Google Scholar
35	An J, Lichtenstein AK, Brent G and Rettig MB: The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: Role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 99:649–654. 2002. View Article : Google Scholar : PubMed/NCBI
36	Vázquez EL, Carey VJ and Kaye KM: Identification of Kaposi's sarcoma-associated herpesvirus LANA regions important for episome segregation, replication, and persistence. J Virol. 87:12270–12283. 2013. View Article : Google Scholar
37	Järviluoma A, Koopal S, Räsänen S, Mäkelä TP and Ojala PM: KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas. Blood. 104:3349–3354. 2004. View Article : Google Scholar : PubMed/NCBI
38	Gopalakrishnan R, Matta H and Chaudhary PM: A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB. Clin Cancer Res. 19:5016–5026. 2013. View Article : Google Scholar : PubMed/NCBI
39	Nicholas J: Human herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia. Front Biosci. 12:265–281. 2007. View Article : Google Scholar
40	Quinlivan EB, Zhang C, Stewart PW, Komoltri C, Davis MG and Wehbie RS: Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis. 185:1736–1744. 2002. View Article : Google Scholar : PubMed/NCBI
41	Higashi C, Saji C, Yamada K, Kagawa H, Ohga R, Taira T and Fujimuro M: The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. Biol Pharm Bull. 35:725–730. 2012. View Article : Google Scholar : PubMed/NCBI
42	Granato M, Chiozzi B, Filardi MR, Lotti LV, Di Renzo L, Faggioni A and Cirone M: Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and Mcl-1 in PEL cells. Cancer Lett. 366:191–197. 2015. View Article : Google Scholar : PubMed/NCBI
43	Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J and Knowles DM: Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 88:645–656. 1996.PubMed/NCBI
44	Goto H, Kariya R, Shimamoto M, Kudo E, Taura M, Katano H and Okada S: Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-κB pathway. Cancer Sci. 103:775–781. 2012. View Article : Google Scholar : PubMed/NCBI